With $290 million in funding and a team of industry veterans, the new company hopes to enter a category of obesity treatments that has taken the country by storm.
Metsera, a clinical-stage biotechnology startup that develops drugs for obesity and metabolic diseases, launched on Thursday with what it described as a “broad portfolio” of weight-loss treatments that it hopes to bring to market.
Originally published on Fast Company : Original article